跳至主要内容
临床试验/NCT05202041
NCT05202041Unknown不适用

Diagnostic Performance and Prognostic Ability of AccuFFRangio for Non-IRA in NSTE-ACS Patients

Wuhan Asia Heart Hospital0 个研究点目标入组 500 人开始时间: 2022年2月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
500
主要终点
Vessel-oriented composite endpoints (VOCEs)

研究概览

简要总结

This is a prospective, single-center clinical trial. AccuFFRangio (ArteryFlow Technology Co., Ltd., Hangzhou, China) is a novel method for evaluating the functional significance of coronary stenosis by computing the pressure in the vessel based on angiographic images. The purpose of this study is to investigate the diagnostic performance and prognostic ability of AccuFFRangio for non-IRA in NSTE-ACS patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 Years and older
  • Non-ST-segment elevation acute coronary syndrome patients with at least 1 non-IRA
  • Diameter stenosis of 50%-90% by visual estimate
  • Reference vessel size > 2 mm in stenotic segment by visual estimate

排除标准

  • LVEF ≤ 40%
  • eGFR < 60 mL/min
  • Allergy to contrast media, adenosine
  • Prior CABG

研究组 & 干预措施

AccuFFRangio Group

Experimental

NSTE-ACS patients with multiple lesions who met the requirements of the study were enrolled and received coronary angiography. First, the revascularization of the criminal vessel (PCI) was completed. The patients were randomly grouped and divided into AccuFFRangio Group and Angiography Group if the treatment results were good. The AccuFFRangio Group was defined as non-IRA of these patients who were treated with PCI after angio-FFR measurement with FFR≤0.8.

干预措施: AccuFFRangio-guided strategy (Other)

Angiography Group

Active Comparator

The Angiography Group was defined as PCI treatment for non-IRA when diameter stenosis > 70% based on angiographic results.

干预措施: Angiography-guided strategy (Other)

结局指标

主要结局

Vessel-oriented composite endpoints (VOCEs)

时间窗: 1 year

Composite of vessel-related cardiovascular death, vessel-related myocardial infarction, and ischemia-driven target vessel revascularization.

Post-PCI AccuFFRangio

时间窗: 1 year

AccuFFRangio limits to yield no VOCEs.

次要结局

  • Cost analysis(1 year)

研究者

申办方类型
Other
责任方
Sponsor

相似试验